Amedeo Smart

Free Medical Literature Service


 

Amedeo

Peptic Ulcer

  Free Subscription

Articles published in
Gut
    June 2022
  1. RUGGE M, Bricca L, Guzzinati S, Sacchi D, et al
    Autoimmune gastritis: long-term natural history in naive Helicobacter pylori-negative patients.
    Gut. 2022 Jun 30. pii: gutjnl-2022-327827. doi: 10.1136/gutjnl-2022-327827.
    >> Share

    April 2022
  2. KALAPALA R, Karyampudi A, Nabi Z, Darisetty S, et al
    Endoscopic full-thickness plication for the treatment of PPI-dependent GERD: results from a randomised, sham controlled trial.
    Gut. 2022;71:686-694.
    >> Share

    March 2022
  3. MEIER B, Wannhoff A, Denzer U, Stathopoulos P, et al
    Over-the-scope-clips versus standard treatment in high-risk patients with acute non-variceal upper gastrointestinal bleeding: a randomised controlled trial (STING-2).
    Gut. 2022 Mar 23. pii: gutjnl-2021-325300. doi: 10.1136/gutjnl-2021-325300.
    >> Share

    January 2022
  4. FORD AC, Tsipotis E, Yuan Y, Leontiadis GI, et al
    Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis.
    Gut. 2022 Jan 12. pii: gutjnl-2021-326583. doi: 10.1136/gutjnl-2021-326583.
    >> Share

    December 2021
  5. DONG C, Lee YH, Tan TY, Yao CC, et al
    Correspondence to proton pump inhibitors and risk of colorectal cancer.
    Gut. 2021 Dec 2. pii: gutjnl-2021-326139. doi: 10.1136/gutjnl-2021-326139.
    >> Share

  6. ABRAHAMI D, Azoulay L
    Response by Abrahami et al to letter regarding article 'Proton pump inhibitors and risk of colorectal cancer'.
    Gut. 2021 Dec 2. pii: gutjnl-2021-326544. doi: 10.1136/gutjnl-2021-326544.
    >> Share

  7. ZERBIB F
    Diagnosis of GORD: is the 'grey area' expanding?
    Gut. 2021;70:2221-2222.
    >> Share

  8. RUSU RI, Fox MR, Tucker E, Zeki S, et al
    Validation of the Lyon classification for GORD diagnosis: acid exposure time assessed by prolonged wireless pH monitoring in healthy controls and patients with erosive oesophagitis.
    Gut. 2021;70:2230-2237.
    >> Share

    November 2021
  9. ZENG R, Sha W, Wang J, Zhuo Z, et al
    Evaluation of proton pump inhibitors and risks of gastric cancer.
    Gut. 2021 Nov 26. pii: gutjnl-2021-326291. doi: 10.1136/gutjnl-2021-326291.
    >> Share

  10. DING SZ, Du YQ, Lu H, Wang WH, et al
    Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management (2021 Edition).
    Gut. 2021 Nov 26. pii: gutjnl-2021-325630. doi: 10.1136/gutjnl-2021-325630.
    >> Share

  11. LOOSEN SH, Kostev K, Luedde M, Qvartskhava N, et al
    Long-term use of proton pump inhibitors (PPIs) is associated with an increased risk of type 2 diabetes.
    Gut. 2021 Nov 1. pii: gutjnl-2021-326297. doi: 10.1136/gutjnl-2021-326297.
    >> Share

    October 2021
  12. SHAH S, Halvorson A, McBay B, Dorn C, et al
    Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort.
    Gut. 2021 Oct 18. pii: gutjnl-2021-325701. doi: 10.1136/gutjnl-2021-325701.
    >> Share

    September 2021
  13. GUO CLT, Wong SH, Lau LHS, Lui RNS, et al
    Timing of endoscopy for acute upper gastrointestinal bleeding: a territory-wide cohort study.
    Gut. 2021 Sep 21. pii: gutjnl-2020-323054. doi: 10.1136/gutjnl-2020-323054.
    >> Share

    August 2021
  14. ARAI J, Niikura R, Hayakawa Y, Aoki T, et al
    OLGIM staging and proton pump inhibitor use predict the risk of gastric cancer.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325551. doi: 10.1136/gutjnl-2021-325551.
    >> Share

    July 2021
  15. PATEL J, Berezowski I, Janapala RN, Pourmand A, et al
    Proton pump inhibitors and gastric cancer: a population-based cohort study.
    Gut. 2021 Jul 14. pii: gutjnl-2021-325385. doi: 10.1136/gutjnl-2021-325385.
    >> Share

  16. OSTER P, Vaillant L, Riva E, McMillan B, et al
    Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies.
    Gut. 2021 Jul 12. pii: gutjnl-2020-323392. doi: 10.1136/gutjnl-2020-323392.
    >> Share

  17. ABRAHAMI D, McDonald EG, Schnitzer ME, Barkun AN, et al
    Proton pump inhibitors and risk of gastric cancer: population-based cohort study.
    Gut. 2021 Jul 5. pii: gutjnl-2021-325097. doi: 10.1136/gutjnl-2021-325097.
    >> Share

  18. ABRAHAMI D, McDonald EG, Schnitzer ME, Barkun AN, et al
    Proton pump inhibitors and risk of colorectal cancer.
    Gut. 2021 Jul 1. pii: gutjnl-2021-325096. doi: 10.1136/gutjnl-2021-325096.
    >> Share

    June 2021
  19. ONG JS, An J, Han X, Law MH, et al
    Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis.
    Gut. 2021 Jun 29. pii: gutjnl-2020-323906. doi: 10.1136/gutjnl-2020-323906.
    >> Share

    May 2021
  20. SEO SI, Park CH, You SC, Kim JY, et al
    Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
    Gut. 2021 May 11. pii: gutjnl-2020-323845. doi: 10.1136/gutjnl-2020-323845.
    >> Share

    April 2021
  21. MEGRAUD F, Bruyndonckx R, Coenen S, Wittkop L, et al
    Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community.
    Gut. 2021 Apr 9. pii: gutjnl-2021-324032. doi: 10.1136/gutjnl-2021-324032.
    >> Share

  22. NIENHUSER H, Kim W, Malagola E, Ruan T, et al
    Mist1+ gastric isthmus stem cells are regulated by Wnt5a and expand in response to injury and inflammation in mice.
    Gut. 2021;70:654-665.
    >> Share

    March 2021
  23. SUNG JJY, Laine L, Kuipers EJ, Barkun AN, et al
    Towards personalised management for non-variceal upper gastrointestinal bleeding.
    Gut. 2021 Mar 1. pii: gutjnl-2020-323846. doi: 10.1136/gutjnl-2020-323846.
    >> Share

    December 2020
  24. SPILLER RC, Jalanka J
    Brachyspira and IBS with diarrhoea: a Helicobacter pylori moment?
    Gut. 2020 Dec 24. pii: gutjnl-2020-323370. doi: 10.1136/gutjnl-2020-323370.
    >> Share

  25. HE Q, Yang M, Qin X, Fan D, et al
    Risk stratification for proton pump inhibitor-associated type 2 diabetes: a population-based cohort study.
    Gut. 2020 Dec 22. pii: gutjnl-2020-323816. doi: 10.1136/gutjnl-2020-323816.
    >> Share

  26. LU TX, Dapas M, Lin E, Peters T, et al
    The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies.
    Gut. 2020 Dec 17. pii: gutjnl-2020-321609. doi: 10.1136/gutjnl-2020-321609.
    >> Share

  27. LEE SW, Yang JM, Yoo IK, Moon SY, et al
    Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort.
    Gut. 2020 Dec 10. pii: gutjnl-2020-323672. doi: 10.1136/gutjnl-2020-323672.
    >> Share

  28. ZHOU J, Wang X, Lee S, Wu WKK, et al
    Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study.
    Gut. 2020 Dec 4. pii: gutjnl-2020-323668. doi: 10.1136/gutjnl-2020-323668.
    >> Share

    November 2020
  29. LI GF, An XX, Yu Y, Jiao LR, et al
    Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis.
    Gut. 2020 Nov 10. pii: gutjnl-2020-323366. doi: 10.1136/gutjnl-2020-323366.
    >> Share

    October 2020
  30. LIOU JM, Malfertheiner P, Lee YC, Sheu BS, et al
    Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus.
    Gut. 2020 Oct 1. pii: gutjnl-2020-322368. doi: 10.1136/gutjnl-2020-322368.
    >> Share

    September 2020
  31. ZHOU X, Zhu H, Chen Y, Li Z, et al
    Role of Helicobacter pylori in gastric diseases pathogenesis cannot be ignored.
    Gut. 2020 Sep 29. pii: gutjnl-2020-322629. doi: 10.1136/gutjnl-2020-322629.
    >> Share

  32. YUAN J, He Q, Nguyen LH, Wong MCS, et al
    Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies.
    Gut. 2020 Sep 28. pii: gutjnl-2020-322557. doi: 10.1136/gutjnl-2020-322557.
    >> Share

  33. NYSSEN OP, Bordin D, Tepes B, Perez-Aisa A, et al
    European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients.
    Gut. 2020 Sep 21. pii: gutjnl-2020-321372. doi: 10.1136/gutjnl-2020-321372.
    >> Share

  34. GRAHAM DY, El-Serag HB
    European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners.
    Gut. 2020 Sep 21. pii: gutjnl-2020-322385. doi: 10.1136/gutjnl-2020-322385.
    >> Share

  35. WU CY, Ho HJ, Wu CY, Chen YJ, et al
    Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor.
    Gut. 2020 Sep 9. pii: gutjnl-2020-321932. doi: 10.1136/gutjnl-2020-321932.
    >> Share

    August 2020
  36. CHIANG TH, Chang WJ, Chen SL, Yen AM, et al
    Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands.
    Gut. 2020 Aug 13. pii: gutjnl-2020-322200. doi: 10.1136/gutjnl-2020-322200.
    >> Share

    July 2020
  37. EUSEBI LH, Cirota GG, Zagari RM, Ford AC, et al
    Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis.
    Gut. 2020 Jul 30. pii: gutjnl-2020-321365. doi: 10.1136/gutjnl-2020-321365.
    >> Share

  38. LEE SW, Ha EK, Yeniova AO, Moon SY, et al
    Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching.
    Gut. 2020 Jul 30. pii: gutjnl-2020-322248. doi: 10.1136/gutjnl-2020-322248.
    >> Share

    May 2020
  39. ROGERS BD, Valdovinos LR, Crowell MD, Bell R, et al
    Number of reflux episodes on pH-impedance monitoring associates with improved symptom outcome and treatment satisfaction in gastro-oesophageal reflux disease (GERD) patients with regurgitation.
    Gut. 2020 May 28. pii: gutjnl-2020-321395. doi: 10.1136/gutjnl-2020-321395.
    >> Share

    April 2020
  40. XIONG J, Wang Y, Chen G, Jin L, et al
    Proton pump inhibitors and the risk of gallbladder cancer: a hospital-based case-control study.
    Gut. 2020 Apr 9. pii: gutjnl-2020-321052. doi: 10.1136/gutjnl-2020-321052.
    >> Share

  41. WONG GLH, Lau LHS, Ching JYL, Tse YK, et al
    Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
    Gut. 2020;69:652-657.
    >> Share

    March 2020
  42. FORD AC, Yuan Y, Moayyedi P
    Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis.
    Gut. 2020 Mar 23. pii: gutjnl-2020-320839. doi: 10.1136/gutjnl-2020-320839.
    >> Share

  43. YAMAJI Y, Hirata Y
    Treatment for Helicobacter pylori appears to reduce the incidence of gastric cancer: eradication effect or screening effect?
    Gut. 2020;69:605-606.
    >> Share

    January 2020
  44. TAO ZH, Fang JY
    The complicated dialogue between Helicobacter pylori and p53.
    Gut. 2020 Jan 23. pii: gutjnl-2020-320630. doi: 10.1136/gutjnl-2020-320630.
    >> Share

  45. SUNG JJY, Coker OO, Chu E, Szeto CH, et al
    Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication.
    Gut. 2020 Jan 23. pii: gutjnl-2019-319826. doi: 10.1136/gutjnl-2019-319826.
    >> Share

  46. SUZUKI S, Gotoda T, Kusano C, Ikehara H, et al
    Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.
    Gut. 2020 Jan 8. pii: gutjnl-2019-319954. doi: 10.1136/gutjnl-2019-319954.
    >> Share

    December 2019
  47. GUO Y, Zhang Y, Gerhard M, Gao JJ, et al
    Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer.
    Gut. 2019 Dec 19. pii: gutjnl-2019-319696. doi: 10.1136/gutjnl-2019-319696.
    >> Share

  48. COSTA L, Corre S, Michel V, Le Luel K, et al
    USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis.
    Gut. 2019 Dec 10. pii: gutjnl-2019-318640. doi: 10.1136/gutjnl-2019-318640.
    >> Share

    November 2019
  49. TONG H, Lan T, Tang CW
    Prophylactic angiographic embolisation after endoscopic treatment of bleeding for high-risk peptic ulcers: what are the more appropriate indications?
    Gut. 2019 Nov 27. pii: gutjnl-2019-319818. doi: 10.1136/gutjnl-2019-319818.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016